Tyrosine kinase inhibitors (TKIs) of BCR-ABL have turned chronic myeloid leukemia (CML) from a deadly disease into a chronic ailment. Unfortunately, evidence is accumulating that TKIs are not curative, since CML stem cells are not addicted to BCR-ABL, and persist despite TKI therapy. On closer view this is not surprising, as it reflects fundamental principles of CML pathogenesis. Strategies to eradicate CML stem cells will most likely be based on synthetic lethality though parallel inhibition of BCR-ABL and other critical pathways.

中文翻译：

---

慢性粒细胞白血病中的干细胞持久性

BCR-ABL 的酪氨酸激酶抑制剂 (TKI) 已将慢性粒细胞白血病 (CML) 从一种致命疾病转变为一种慢性疾病。不幸的是，越来越多的证据表明 TKI 不能治愈，因为 CML 干细胞不会对 BCR-ABL 上瘾，并且尽管 TKI 治疗仍然存在。仔细观察这并不奇怪，因为它反映了 CML 发病机制的基本原理。通过平行抑制 BCR-ABL 和其他关键途径，根除 CML 干细胞的策略很可能基于合成杀伤力。